Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/2/2025 | Overweight | Analyst | |
| 7/3/2025 | $7.00 | Overweight | Morgan Stanley |
| 1/22/2025 | $9.00 | Buy | Needham |
| 10/2/2024 | $10.00 | Buy | Guggenheim |
| 7/3/2024 | $7.00 | Overweight | Morgan Stanley |
| 3/14/2024 | $13.00 | Sector Outperform | Scotiabank |
| 12/5/2023 | $3.00 | Overweight | KeyBanc Capital Markets |
| 5/4/2023 | $4.00 | Buy | H.C. Wainwright |
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201's potential to reverse follicular miniaturization and drive vellus-to-terminal hair regeneration by demonstrating that it prolongs anagen, stimulates keratin synthesis, and modulates the stem cell niche Full dataset will be presented during today's ABS-201 Key Opinion Leader (KOL) seminar VANCOUVER, Wash. and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today unveiled new preclinical data for ABS-
Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease Donovan to share his personal journey at Absci's upcoming Key Opinion Leader seminar VANCOUVER, Wash. and NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced a partnership with U.S. soccer legend Landon Donovan to elevate the voices of those living with androgenetic alopecia (AGA) and shine a light on the emotional impact of hair loss. Donovan will join Absci's virtual KOL seminar on Thursday, December 11 t
Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia (AGA) and Phase 2 for endometriosis KOL seminar scheduled for December 11 to discuss new human ex vivo data, clinical trial design, and market opportunity in AGA VANCOUVER, Wash. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in the Phase 1/2a HEADLINE study eva
Analyst initiated coverage of Absci Corporation with a rating of Overweight
Morgan Stanley resumed coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00
Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00
10-Q - Absci Corp (0001672688) (Filer)
8-K - Absci Corp (0001672688) (Filer)
8-K - Absci Corp (0001672688) (Filer)
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal roles in advancing transformative therapies, notably guiding the global launch and expansion of Humira® into multiple indications during her tenure at Abbott Laboratories. "Mary has been a driving force behind the development of one of the most successful therapies in the industry, bringing a rare and invaluable bread
Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e
VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a
Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 Expanding ABS-201 strategy to pursue endometriosis as additional indication; anticipate initiation of Phase 2 clinical trial in the fourth quarter of 2026 Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operat
VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2025 after market close on Wednesday, November 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived
VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The we
SC 13G - Absci Corp (0001672688) (Subject)
SC 13G/A - Absci Corp (0001672688) (Subject)
SC 13D/A - Absci Corp (0001672688) (Subject)